Enhancement of Cisplatin Efficacy by the Histone Demethylase Inhibitor JIB-04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines
Cells · 06.11.2026 · 15 (21) · 2023
DOI: 10.3390/cells15212023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 06.11.2026. Verfasst von Kamila Adamczuk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Cisplatin, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Jumonji Domain-Containing Histone Demethylases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowa Agencja Wymiany Akademickiej, Polish National Agency for Academic Exchange.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) develops resistance to cisplatin. We investigated whether JIB-04, an inhibitor of Jumonji histone demethylases, enhances cisplatin activity in established HNSCC cell lines. Four UT-SCC cell lines originating from primary tumors and matched lymph-node metastases were treated with JIB-04 and cisplatin, alone or combined. Viability was assessed by MTT assay, and drug interactions were evaluated using the Highest Single Agent model. In UT-SCC-24A cells, we assessed BrdU incorporation, LDH release, cell-cycle distribution, and apoptosis. RNA sequencing was performed after 24 h at the same drug concentrations used in functional assays. JIB-04 reduced viability in all HNSCC lines at submicromolar concentrations, with moderate effects in BJ fibroblasts. HSA analysis identified a localized positive interaction in UT-SCC-24A, where the overall HSA score was 4.25, whereas local scores reached approximately 16–18 within a narrow low-dose range. Co-treatment further reduced DNA synthesis and increased S/G2-M accumulation and apoptosis, without significantly increasing LDH release. RNA sequencing revealed JIB-04-associated induction of integrated stress response/ATF4- and DNA damage response-related genes, alongside suppression of proliferation- and cell-cycle-associated genes. The combination retained these transcriptional features. These findings support the further investigation of JIB-04–cisplatin combinations in selected HNSCC cell-line models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland.
- Department of Physiology and Toxicology, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
ORCID-Profile: Grzegorz Adamczuk, Michał Kiełbus, Matthias Nees, Andrzej Stepulak
Förderung
- Narodowa Agencja Wymiany Akademickiej
- Polish National Agency for Academic Exchange
Zitieren
APA
Adamczuk, K., Adamczuk, G., Kiełbus, M., Nees, M., & Stepulak, A. (2026). Enhancement of Cisplatin Efficacy by the Histone Demethylase Inhibitor JIB-04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines. Cells, 15(21), 2023. https://doi.org/10.3390/cells15212023
Vancouver
Adamczuk K, Adamczuk G, Kiełbus M, Nees M, Stepulak A. Enhancement of Cisplatin Efficacy by the Histone Demethylase Inhibitor JIB-04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines. Cells. 2026;15(21):2023. doi:10.3390/cells15212023
BibTeX
@article{Adamczuk2026,
author = {Adamczuk, Kamila and Adamczuk, Grzegorz and Kiełbus, Michał and Nees, Matthias and Stepulak, Andrzej},
title = {Enhancement of Cisplatin Efficacy by the Histone Demethylase Inhibitor JIB-04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines},
journal = {Cells},
year = {2026},
volume = {15},
number = {21},
pages = {2023},
doi = {10.3390/cells15212023}
}
EUVIMED